ReviewFrontiers in immunology2026
Seaweed sulfated polysaccharides regulate the gut microbiota-mucosal barrier-innate immunity axis: structural heterogeneity, immunological evidence, and translational prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seaweed sulfated polysaccharides, fucoidan, carrageenan, ulvan, and porphyran, are structurally diverse marine glycans that modulate the gut microbiota, mucosal barrier, and innate immunity, yet the literature remains fragmented across classes, models, and processing histories. This review synthesizes evidence on their structure-function relationships, focusing on microbial enzymatic accessibility, selective fermentation, metabolite remodeling, barrier regulation, and immune signaling, while also assessing translational barriers. A systematic literature search prioritized mechanistic studies, structural analyses, animal models, human trials, and high-quality reviews. Our analysis reveals that porphyran provides the clearest microbiota-barrier coupling, fucoidan and carrageenan give the richest, but most heterogeneous, immune readouts, and ulvan is an emerging class with growing intestinal evidence. Molecular weight, sulfation pattern, and degradation history consistently shape microbial utilization and downstream effects across all classes. Disease contexts with the strongest support include inflammatory bowel disease, constipation, barrier injury, and infection-driven intestinal inflammation. Time-dependent immune shifts have been reported, but durable epigenetic memory remains unproven, and extra-intestinal evidence through gut-liver and gut-brain axes is still preliminary. We conclude that these polysaccharides are best understood as structurally defined substrates that bridge the microbiota, barrier, and immunity; future progress toward clinical translation will depend on stricter standardization, integrated mechanistic designs, and robust human data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.